Skip to main content
Clinical Trials/NCT01825005
NCT01825005
Completed
Not Applicable

Predicting Outcome in Cervix Carcinoma: a Prospective Study

Maastricht Radiation Oncology2 sites in 2 countries423 target enrollmentFebruary 2013
ConditionsCervical Cancer

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Cervical Cancer
Sponsor
Maastricht Radiation Oncology
Enrollment
423
Locations
2
Primary Endpoint
five-year overall survival rate
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

The main aim is to validate and improve the predictive model for survival and toxicity in patients with cervical cancer through multicentric prospective data collection. The data contain information on patient, tumor and treatment characteristics. For this study, additional health related QOL scores will be assessed using the EORTC Quality of Life Questionair-CX24 and C30. The long term aim, beyond this specific study, is to build a Decision Support System based on the predictive model validated in this study.

Registry
clinicaltrials.gov
Start Date
February 2013
End Date
August 2018
Last Updated
6 years ago
Study Type
Observational
Sex
Female

Investigators

Sponsor
Maastricht Radiation Oncology
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • histological or cytological proven cervical cancer
  • informed consent according to national rules

Exclusion Criteria

  • no histological or cytological proven cervical cancer
  • no informed consent according to national rules

Outcomes

Primary Outcomes

five-year overall survival rate

Time Frame: 5 years after treatment

assessment of the overall survival 5 years after treatment

Secondary Outcomes

  • three-year distant disease free survival(3 years)
  • three-year local disease free survival(3 years)
  • five-year distant disease free survival(5 years)
  • five-year local disease free survival(5 years)
  • number of participants with early adverse events as a measure of safety and tolerability(2 months)
  • number of participants with late adverse events as a measure of safety and tolerability(5 years)

Study Sites (2)

Loading locations...

Similar Trials